A clinical study into the use of lab-grown retina cells to treat age-related macular degeneration has been slated for fiscal 2013, a senior staffer of the research body planning to undertake the project said Saturday.
The project might be the world’s first to use induced pluripotent stem cells, or iPS cells, for the treatment of human diseases. The Center for Developmental Biology of Riken will report its plan to the health ministry in fiscal 2012 starting in April.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
If this does not resolve the issue or you are unable to add the domains to your allowlist, please see this support page.
We humbly apologize for the inconvenience.
In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.
SUBSCRIBE NOW
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.